Navigation Links
Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/16/2010

BASKING RIDGE, N.J., Nov. 16, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Thomas J. Povsic, MD, Ph.D., Duke University Medical Center, presented an abstract at the AHA Scientific Sessions meeting on November 16, 2010 at 10:45 a.m. CST in Chicago, IL.

The abstract, entitled "RB006, a Direct Factor IX Inhibitor Results in Consistent and Near Complete Inhibition of Factor IX in Patients with Acute Coronary Syndromes: A RADAR Pharmacokinetic and Pharmacodynamic Substudy," evaluated the appropriateness of the selected dose of pegnivacogin (a.k.a. RB006) for use in patients with Acute Coronary Syndromes.  RB006 is part of the REG1 anticoagulation system.

Regado's ongoing Phase 2b clinical trial titled: "Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects with Acute Coronary Syndrome," (a.k.a. RADAR) is a partially blinded study currently enrolling 800 patients in more than 90 centers worldwide.  Patients were randomly allocated [4:1] to receive open-label RB006 or unfractionated heparin prior to catheterization and underwent various levels of double blind reversal at the end of the procedure.  This substudy, conducted in the open label portion of RADAR, included thirty patients, 20 of whom had not received recent unfractionated heparin.  It assessed PK/PD measurements just prior to and 10 minutes after dosing with RB006.  PK/PD assessments were also made, both prior to and after cardiac catheterization and before blinded dosing of anivamersen (a.k.a. RB007), RB006's complementary active control agent.  The objective was to evaluate the appropriateness of the selected RB006 dose.  

The data from this abstract demonstrated that RB006 (1mg/kg, IV) results in consistent and near complete inhibition of FIX in patients with ACS with stable anti-coagulation throughout catheterization (PCI).  These findings further validate the dosing of RB006 for Regado's ongoing and planned clinical trials.

The abstract is coauthored by Thomas J. Povsic, MD, Ph.D., Richard A. Becker, MD, and John H. Alexander, MD, MHS, all from Duke University Medical Center; Christopher P. Rusconi, Ph.D., Steven L. Zelenkofske, D.O., both from Regado Biosciences; and William Wargin, Ph.D., President of PK-PM Associates, LLC; Mauricio G. Cohen, MD, University of Miami Miller School of Medicine; Roxana Mehran, MD, Mount Sinai School of Medicine; Christoph Bode, MD, University of Freiburg, Germany; Joshua Krasnow, MD, Heart Center Research, LLC; and Merrill Krolick, D.O., Heart and Vascular Institute of Florida.  

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients intended for Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERSPegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the active control agent of pegnivacogin.  

More information can be found at www.regadobio.com.Contact:Ellen McDonaldChief Business OfficerRegado Biosciences1-908-580-2113emcdonald@regadobio.comMedia Contact:Tiberend Strategic Advisors, Inc.1-212-827-0020Andrew Mielachamielach@tiberendstrategicadvisors.com
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
2. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
3. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
6. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
7. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
10. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
11. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... NEW YORK , Feb. 21, 2017 /PRNewswire/ ... company focused on the development of innovative immuno-oncology ... and statistically significant data from its Phase 2 ... , for the treatment of non-small cell lung ... oral presentation at this year,s ASCO-SITC Clinical Immuno-Oncology ...
(Date:2/21/2017)... , Feb. 21, 2017 EMS Find, ... and web based platforms with focus on e-commerce, ... the signing of a worldwide, on-revocable and renewable ... full-service medical transportation company serving healthcare organizations and ... . EpicMD,s platform eliminates the ...
(Date:2/21/2017)... According to a new market research report "Medical Robots Market by Product (Instruments ... Robots)), Application (Orthopedic, Laparoscopy, Neurology) - Global Forecasts to 2021", published by MarketsandMarkets, ... ... MarketsandMarkets Logo ... report studies the global medical robots market for the forecast period of 2016 ...
Breaking Medicine Technology:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... solutions for supply chain management (SCM) and spend management, today announced that Keppel ... save time, and simplify expense tracking. , “We are excited to announce ...
(Date:2/21/2017)... ... ... Author Michèle Wolff has a passion for using food as medicine ... about it for optimal health. Wanting to share her knowledge to the world, she ... Solutions ” (published by Balboa Press AU). , This book inspires readers to ...
(Date:2/21/2017)... ... 2017 , ... Tripp Lite, a world-leading manufacturer of power ... meet the most current standards. , The adoption by the Centers for Medicare ... Association (NFPA) 101 – Life Safety Code (LSC) and NFPA 99 – Health ...
(Date:2/21/2017)... Visalia, CA (PRWEB) , ... February 21, 2017 , ... ... Tulare , CA, directed by Dr. Kendell Mendonca , to its growing network ... worker’s compensation injuries including injuries stemming from car accidents such as whiplash, back pain, ...
(Date:2/21/2017)... ... 2017 , ... Individuals who have been diagnosed with cancer ... therapy and management. Regular exercise in proper environments has been shown to benefit ... On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx webinar ...
Breaking Medicine News(10 mins):